Side effects ‐ hirsutism · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes side effects: hirsutism compared with danazol (very low certainty).
1 finding from 1 review
Decreased breast size · women with symptomatic endometriosis
Gestrinone may leads to lower decreased breast size compared with danazol (low certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: reduction of productivity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: social activities (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: relationship interference (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (observer‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (self‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Resumption of menstrual regularity · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Resumption of spontaneous ovulation · women with polycystic ovary syndrome not actively trying to conceive
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Improvement in acne severity · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Improvement in testosterone level (nmol/L) after 6 months' treatment · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Adverse effects · women with polycystic ovary syndrome not actively trying to conceive
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · acute fractures in adults; included studies assessed effects in complete upper limb fractures (distal radius, clavicle, scaphoid,…
1 finding from 1 review